Pioglitazone vs. Rosiglitazone in Older Patients with Type 2 Diabetes
Explore this paper's citation graph
Summary
In this retrospective cohort study, Canadian investigators assessed risk for myocardial infarction, heart failure, and death in nearly 40,000 older patients.
- Type
- article
- Published
- 2009-01-01
- Cited by
- 0
- References
- 1
- OpenAlex
- https://openalex.org/W2340355954
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:76382859
Keywords
Pioglitazone, Rosiglitazone, Medicine, Type 2 diabetes, Myocardial infarction
References
Cited by
No citing papers recorded for this paper.
Related papers
- Pioglitazone was associated with lower risk for adverse cardiovascular events than rosiglitazone in older patients
- Cardiovascular safety of rosiglitazone and pioglitazone
- Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy
- Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
- Cardiovascular risk and cardiometabolic protection: role of glitazones.
- Evaluation of Thiazolidinediones on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review
- Rosiglitazone, Pioglitazone, and Fractures: A Meta-Analysis
- Rosiglitazone: More Data, Continuing Concern
- Cardiovascular Safety Data on Rosiglitazone Aren’t Entirely Reassuring